Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 12, 2020 at 05:20 pm EST
Share
Xenetic Biosciences, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced total revenue was USD 115,934. Operating loss was USD 10.504 million compared to USD 8.946 million a year ago. Net loss was USD 7.560 million compared to USD 8.900 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 2.67 a year ago. For the nine months, total revenue was USD 285,610. Operating loss was USD 12.717 million compared to USD 11.651 million a year ago. Net loss was USD 9.693 million compared to USD 11.604 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 9.07 a year ago.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
